This clinical trial is focused on studying Chronic Heart Failure, a condition where the heart doesn’t pump blood as well as it should. The study will test a new treatment called AZD5462, which is taken as a film-coated tablet. The purpose of the study is to evaluate the effect and dose response of AZD5462 after 24 weeks of treatment in participants with heart failure.

Participants in the study will be randomly assigned to receive either the AZD5462 tablet or a placebo, which looks like the real medication but does not contain the active ingredient. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not biased. The study will last for about 24 weeks, during which participants will take the medication orally.

Throughout the study, participants will have regular check-ups to monitor their heart health and overall well-being. These check-ups will include various tests to measure changes in heart function and health status. The goal is to see how AZD5462 affects heart failure symptoms and to determine the best dose for treatment. The study aims to provide valuable information that could lead to improved treatments for people living with chronic heart failure.